Jennison Associates
WX

Jennison Associates’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Jennison Associates’s Portfolio WX Stock Details WX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1,644,155
Closed -$71M – 776
2015
Q3 		$71M Buy
1,644,155
+59,956
+4% +$2.53M 0.07% 237
2015
Q2 		$66.9M Buy
1,584,199
+12,832
+0.8% +$541K 0.06% 282
2015
Q1 		$60.9M Buy
1,571,367
+661,894
+73% +$25.5M 0.06% 297
2014
Q4 		$30.6M Sell
909,473
-17,966
-2% -$635K 0.03% 398
2014
Q3 		$32.5M Buy
927,439
+5,239
+0.6% +$180K 0.03% 390
2014
Q2 		$30.3M Buy
922,200
+135,098
+17% +$4.62M 0.03% 397
2014
Q1 		$29M Buy
787,102
+4,159
+0.5% +$153K 0.03% 405
2013
Q4 		$30M Buy
782,943
+8,380
+1% +$265K 0.03% 400
2013
Q3 		$21.2M Buy
774,563
+7,264
+0.9% +$172K 0.02% 428
2013
Q2 		$16.1M Buy
+767,299
New +$15M 0.02% 452

Other funds holding WX

Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
CCS
Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return

Jennison Associates's WX Position: Q4 2015 in Review

Jennison Associates sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q4 2015, closing a stake of 1,644,155 shares — an estimated $71M sold.

Jennison Associates first reported a position in WX in Q2 2013 and held it in 10 quarters. The position peaked at $71M in Q3 2015. 2 funds tracked by Wall St. Rank hold WX as of Q4 2015.

  • Jennison Associates reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q4 2015 after selling out during the quarter.
  • Jennison Associates sold 1,644,155 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q4 2015, an estimated $71M.
  • Jennison Associates first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q2 2013 and held it in 10 quarters.
  • Jennison Associates's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $71M in Q3 2015.
  • 2 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q4 2015.

Based on Jennison Associates's 13F filing for Q4 2015, filed 10 Feb 2016.